The folks at GlaxoSmithKline must be celebrating today: Rival Novartis has handed back U.S. rights to a drug that might have become a copycat version of the GSK blockbuster Advair. That move gives Glaxo one less problem to worry about. . GSK chief Andrew Witty has been pooh poohing the potential of generic rivals to that best selling lung drug, which accounted for $7.6 billion in 2009 sales. 
Share:  The folks at <span class="company">GlaxoSmithKline</span> must be celebrating today: Rival Novartis has handed back U.S. rights to a drug that might have become a copycat version of the GSK blockbuster Advair. That move gives Glaxo one less problem to worry about. . GSK chief Andrew Witty has been pooh poohing the potential of generic rivals to that best selling lung drug, which accounted for $7.6 billion in 2009 sales. Tweet this 

At the same time there was positive news from Glaxo about its Relovair drug. Analyst Savvas Neophytou at Panmure Gordon said:We expect Glaxo to be strong this morning with two bits of news that massively de risk the Advair franchise, which represents 17% of group revenues.One, 
Share:  At the same time there was positive news from <span class="company">Glaxo</span> about its Relovair drug.<span class="sent"> Analyst <span class="analyst">Savvas Neophytou</span> at Panmure Gordon said:We expect <span class="company">Glaxo</span> to be strong this morning with two bits of news that massively de risk the Advair franchise, which represents 17% of group revenues.One,</span> Tweet this 

Take Tara Dall, who entered private practice in 2001 and was paid $45,000 for three months of speaking last year by GlaxoSmithKline, which ranked her among the most highly paid among 3,600 speakers for the drugmaker, The Milwaukee Journal Sentinel reports. Critics say the trend is troublesome, because the talks can be biased and contribute to rising health care costs by promoting expensive brand name drugs, but there are no restrictions on private docs. "There are no skids on them," Jerome Kassirer, a former editor of the New England Journal of Medicine, tells the paper. 
Share:  Take Tara Dall, who entered private practice in 2001 and was paid $45,000 for three months of speaking last year by <span class="company">GlaxoSmithKline</span>, which ranked her among the most highly paid among 3,600 speakers for the drugmaker, The Milwaukee Journal Sentinel reports. Critics say the trend is troublesome, because the talks can be biased and contribute to rising health care costs by promoting expensive brand name drugs, but there are no restrictions on private docs. "There are no skids on them," Jerome Kassirer, a former editor of the New England Journal of Medicine, tells the paper. Tweet this 

The most eagerly awaited candidate is the lupus pipeline drug Benlysta, co developed with GlaxoSmithKline Plc ( ), which has blockbuster potential. The company intends to seek approval for Benlysta during the second quarter of 2010 in the United States and Europe. Management expects the drug to be approved in the U. S in the fourth quarter of 2010. 
Share:  The most eagerly awaited candidate is the lupus pipeline drug Benlysta, co developed with <span class="company">GlaxoSmithKline Plc</span> ( ), which has blockbuster potential. The company intends to seek approval for Benlysta during the second quarter of 2010 in the United States and Europe. Management expects the drug to be approved in the U. S in the fourth quarter of 2010. Tweet this 

Revenues for the reported quarter came in at $10.5 million which represents the payments recognized from the sale of its PentaStaph drug to GlaxoSmithKline Biologicals S. A., a subsidiary of GlaxoSmithKline plc ( GSK , Analyst Report ). The amount is inclusive of $3.1 million from the initial $21.5 million payment from GlaxoSmithKline Biologicals S. A., a $5 million payment for the successful achievement of a performance milestone and $2.4 million related to the services provided by Nabi under the transition services agreement. The company reported no revenues in the year ago quarter. 
Share:  Revenues for the reported quarter came in at $10.5 million which represents the payments recognized from the sale of its PentaStaph drug to GlaxoSmithKline Biologicals S. A., a subsidiary of <span class="company">GlaxoSmithKline plc</span> ( GSK , Analyst Report ). The amount is inclusive of $3.1 million from the initial $21.5 million payment from GlaxoSmithKline Biologicals S. A., a $5 million payment for the successful achievement of a performance milestone and $2.4 million related to the services provided by Nabi under the transition services agreement. The company reported no revenues in the year ago quarter. Tweet this 

More Indian news from GlaxoSmithKline. CEO Andrew Witty is traveling this week in India, meeting with reporters along the way, and that's put GSK in the headlines almost daily. Witty's been talking deals (he's in favor of them) and drug prices (they have to be flexible) and strategy (grow via deals and organically in poor and middle income countries). . Now, Witty tells the local Economic Times that he has a long, long time line for his India strategy. 
Share:  More Indian news from <span class="company">GlaxoSmithKline</span>. CEO Andrew Witty is traveling this week in India, meeting with reporters along the way, and that's put GSK in the headlines almost daily. Witty's been talking deals (he's in favor of them) and drug prices (they have to be flexible) and strategy (grow via deals and organically in poor and middle income countries). . Now, Witty tells the local Economic Times that he has a long, long time line for his India strategy. Tweet this 

GlaxoSmithKline has cut prices to boost sales in the poorest countries on the globe. Now it's homing in on middle income countries as another way to grow its revenues. And the company's strategy in these nations mirrors its approach in the poorer ones: Make medicines more affordable, improve access to them, and higher sales will come. 
Share:  <span class="company">GlaxoSmithKline</span> has cut prices to boost sales in the poorest countries on the globe. Now it's homing in on middle income countries as another way to grow its revenues. And the company's strategy in these nations mirrors its approach in the poorer ones: Make medicines more affordable, improve access to them, and higher sales will come. Tweet this 

Eau de Glaxo cnbc.com . It's not quite the same as waiting for new, entertaining commercials during the Super Bowl, but there was a noteworthy premiere during last night's Academy Awards. GlaxoSmithKline [ GSK 37.41 0.13 ( 0.35%) ] unveiled the latest in a series of unbranded, disease awareness commercials in the middle of the oh so long telecast. 
Share:  Eau de <span class="company">Glaxo</span> cnbc.com . It's not quite the same as waiting for new, entertaining commercials during the Super Bowl, but there was a noteworthy premiere during last night's Academy Awards. <span class="company">Glaxo</span>SmithKline [ GSK 37.41 0.13 ( 0.35%) ] unveiled the latest in a series of unbranded, disease awareness commercials in the middle of the oh so long telecast. Tweet this